{
    "source": "Novo Nordisk Lexicon (Semaglutide/Obesity) v7.0",
    "rules": [
        {
            "category": "Body composition",
            "to": "intramuscular adipose tissue (IMAT)",
            "from": [
                "fat infiltration",
                "fatty muscle fraction",
                "myosteatosis",
                "adipose tissue in muscle",
                "intramyocellular lipids",
                "muscle fat"
            ],
            "acronym": "IMAT"
        },
        {
            "category": "People-first language",
            "to": "people living with obesity",
            "from": [
                "obese patients",
                "obese subjects",
                "patients with obesity"
            ],
            "notes": "Always use people-first language"
        },
        {
            "category": "Therapy class",
            "to": "anti-obesity medication (AOM)",
            "from": [
                "weight loss drug",
                "weight-loss drug",
                "weight loss medication",
                "weight-loss medication",
                "Anti-obesity therapy"
            ],
            "acronym": "AOM"
        },
        {
            "category": "Therapy class",
            "to": "weight-management medication",
            "from": [
                "Weight-management medication"
            ],
            "notes": "Avoid using: Weight-loss medication"
        },
        {
            "category": "Endpoints",
            "to": "major adverse cardiovascular events (MACE)",
            "from": [
                "cardiac events",
                "heart problems",
                "major cardiovascular events"
            ],
            "acronym": "MACE",
            "notes": "Specify 3-point or 5-point when stated. Always plural."
        },
        {
            "category": "Endpoints",
            "to": "three-point MACE",
            "from": [
                "3-point mace",
                "3 point mace",
                "three-point mace"
            ],
            "acronym": "MACE"
        },
        {
            "category": "Endpoints",
            "to": "five-point MACE",
            "from": [
                "5-point mace",
                "5 point mace",
                "five-point mace"
            ],
            "acronym": "MACE"
        },
        {
            "category": "CV outcomes",
            "to": "myocardial infarction (MI)",
            "from": [
                "mi",
                "heart attack",
                "acute myocardial infarction"
            ],
            "acronym": "MI"
        },
        {
            "category": "CV outcomes",
            "to": "non-fatal myocardial infarction (MI)",
            "from": [
                "non-fatal mi",
                "nonfatal mi"
            ],
            "acronym": "MI"
        },
        {
            "category": "CV outcomes",
            "to": "non-fatal stroke",
            "from": [
                "stroke (non-fatal)",
                "non-fatal stroke",
                "nonfatal stroke"
            ]
        },
        {
            "category": "Blood pressure",
            "to": "systolic blood pressure (SBP)",
            "from": [
                "blood pressure",
                "sbp"
            ],
            "acronym": "SBP"
        },
        {
            "category": "Renal",
            "to": "renal outcomes",
            "from": [
                "kidney outcomes",
                "kidney events"
            ]
        },
        {
            "category": "Evidence type",
            "to": "real-world evidence (RWE) study",
            "from": [
                "real world analysis",
                "real world data",
                "real-world data study"
            ],
            "acronym": "RWE"
        },
        {
            "category": "Study design",
            "to": "non-interventional study",
            "from": [
                "observational study"
            ]
        },
        {
            "category": "Study design",
            "to": "randomised controlled trial (RCT)",
            "from": [
                "clinical trial",
                "trial (randomized)"
            ],
            "acronym": "RCT"
        },
        {
            "category": "Analysis type",
            "to": "secondary (post-hoc) analysis",
            "from": [
                "secondary analysis",
                "posthoc analysis",
                "post-hoc analysis",
                "post-hoc analyses",
                "Analyses were performed post hoc"
            ]
        },
        {
            "category": "Drug reference",
            "to": "once-weekly subcutaneous semaglutide 2.4 mg",
            "from": [
                "semaglutide 2.4",
                "wegovy 2.4",
                "weekly semaglutide",
                "s.c. semaglutide DOSE once weekly"
            ]
        },
        {
            "category": "Drug reference",
            "to": "Oral semaglutide DOSE (e.g. oral semaglutide 3 mg once daily)",
            "from": [
                "Oral semaglutide DOSE"
            ]
        },
        {
            "category": "Drug reference",
            "to": "liraglutide 3.0 mg",
            "from": [
                "liraglutide 3 mg",
                "liraglutide 3.0"
            ]
        },
        {
            "category": "Drug reference",
            "to": "tirzepatide (dual GIP/GLP-1 receptor agonist)",
            "from": [
                "tirzepatide"
            ],
            "acronym": "tirzepatide"
        },
        {
            "category": "Drug reference",
            "to": "GLP-1 receptor agonists",
            "from": [
                "GLP-1 receptor agonists",
                "GLP-1-based therapies"
            ],
            "acronym": "GLP-1RA",
            "notes": "Avoid using: 'mimetics', 'GLP-1 RA' (with a space)"
        },
        {
            "category": "Drug reference",
            "to": "Semaglutide",
            "from": [
                "Semaglutide"
            ],
            "notes": "When referring to product in specific indication, include dose. Avoid brand names (Ozempic, Rybelsus, Wegovy) in publications."
        },
        {
            "category": "Comparative methods",
            "to": "network meta-analysis (NMA)",
            "from": [
                "indirect treatment comparison",
                "indirect comparison",
                "network meta analysis",
                "network meta-analysis"
            ],
            "acronym": "NMA"
        },
        {
            "category": "Comparative methods",
            "to": "model-based network meta-analysis (MBNMA)",
            "from": [
                "model based network meta analysis",
                "model-based network meta analysis",
                "mbnma method"
            ],
            "acronym": "MBNMA"
        },
        {
            "category": "Stats",
            "to": "intention-to-treat (ITT) analysis",
            "from": [
                "itt"
            ],
            "acronym": "ITT"
        },
        {
            "category": "Stats",
            "to": "per-protocol (PP) analysis",
            "from": [
                "per protocol",
                "pp analysis"
            ],
            "acronym": "PP"
        },
        {
            "category": "Stats",
            "to": "propensity score matching (PSM)",
            "from": [
                "propensity matching",
                "psm"
            ],
            "acronym": "PSM"
        },
        {
            "category": "HRV & devices",
            "to": "heart rate variability (HRV)",
            "from": [
                "heart rate variability",
                "hrv"
            ],
            "acronym": "HRV"
        },
        {
            "category": "HRV & devices",
            "to": "electrocardiogram (ECG)",
            "from": [
                "electrocardiogram",
                "ecg",
                "ekg"
            ],
            "acronym": "ECG"
        },
        {
            "category": "Publications",
            "to": "manuscript",
            "from": [
                "paper",
                "publication (journal)"
            ]
        },
        {
            "category": "Publications",
            "to": "abstract",
            "from": [
                "conference abstract",
                "meeting abstract"
            ]
        },
        {
            "category": "Publications",
            "to": "poster",
            "from": [
                "poster presentation",
                "conference poster"
            ]
        },
        {
            "category": "Publications",
            "to": "oral presentation",
            "from": [
                "oral",
                "talk",
                "podium"
            ]
        },
        {
            "category": "Cardiovascular & Kidney Disease",
            "to": "Cardiovascular disease",
            "from": [
                "Cardiovascular disease"
            ],
            "acronym": "CVD",
            "notes": "Use 'CVD', but use 'ASCVD' when specifically referring to atherosclerotic cardiovascular disease."
        },
        {
            "category": "Cardiovascular & Kidney Disease",
            "to": "Atherosclerotic cardiovascular disease",
            "from": [
                "Atherosclerotic cardiovascular disease"
            ],
            "acronym": "ASCVD"
        },
        {
            "category": "Cardiovascular & Kidney Disease",
            "to": "Heart failure with preserved ejection fraction",
            "from": [
                "HFpEF",
                "Heart failure with preserved ejection fraction"
            ],
            "acronym": "HFpEF",
            "notes": "Note lower case 'p'. Avoid: HFPEF, 'Obese phenotype of HFpEF'. HFpEF is a syndrome."
        },
        {
            "category": "Cardiovascular & Kidney Disease",
            "to": "Chronic kidney disease",
            "from": [
                "Chronic kidney disease"
            ],
            "acronym": "CKD"
        },
        {
            "category": "Cardiovascular & Kidney Disease",
            "to": "Diabetic kidney disease",
            "from": [
                "Diabetic kidney disease"
            ],
            "acronym": "DKD",
            "notes": "Avoid: Diabetic nephropathy"
        },
        {
            "category": "Publication Style",
            "to": "phase 3",
            "from": [
                "phase 3",
                "Phase III"
            ],
            "notes": "Lower-case description and Arabic number. Do not capitalise or use Roman numerals."
        },
        {
            "category": "Publication Style",
            "to": "vs",
            "from": [
                "vs",
                "versus",
                "vs."
            ],
            "notes": "No dot."
        },
        {
            "category": "Publication Style",
            "to": "p value",
            "from": [
                "P value",
                "P-value",
                "p-value"
            ],
            "notes": "Lowercase p, no hyphen. Do not italicise."
        }
    ]
}